Publikationen

Publikationen mit Forschungsförderung durch die Boris Canessa ALS Stiftung

ALS motor phenotypes: a revised ‘OPM’ classification

Autor*innen

Thomas Meyer, Nicola Ticozzi, Markus Weber, John Ravits, Paul Lingor, Magdalena Kuźma-Kozakiewicz, Matthias Boentert, Torsten Grehl, Philippe Corcia, Mónica Povedano Panadés, André Maier, Caroline Ingre, Hakan Cetin, Patrick Weydt, Christian Lunetta, Leonard van den Berg, Albert C. Ludolph, David Brenner, Martin R Turner, Angela Genge

Medium

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, März 2026

doi

10.1080/21678421.2026.2644277

PMID

41843813

PDF Publikation

Publi­ka­tio­nen mit For­schungs­för­de­rung durch die Boris Canes­sa ALS Stif­tung

ALS motor phe­no­ty­pes: a revi­sed ‘OPM’ clas­si­fi­ca­ti­on

Mini­mum important slo­wing of dise­a­se pro­gres­si­on as deter­mi­ned by the ALS func­tion­al rating sca­le — a sur­vey of pati­ent expec­ta­ti­ons toward dise­a­se-modi­fy­ing drugs in ALS

Motor phe­no­ty­pes and neu­ro­fi­la­ment light chain in gene­tic amyo­tro­phic late­ral sclerosis—results from a mul­ti­cen­ter scree­ning pro­gram

Agree­ment Bet­ween the Har­mo­ni­zed and the Self-Expl­ana­to­ry Ver­si­ons of the Revi­sed ALS Func­tion­al Rating Sca­le in a Cli­ni­cal Set­ting

Dextromethorphan/quinidine (DMQ) for redu­cing bul­bar sym­ptoms in amyo­tro­phic late­ral scle­ro­sis — assess­ment of tre­at­ment expe­ri­ence in a mul­ti­cen­ter stu­dy

Motor phe­no­ty­pes of amyo­tro­phic late­ral scle­ro­sis — a three-deter­mi­nant ana­to­mic­al clas­si­fi­ca­ti­on based on the regi­on of onset, pro­pa­ga­ti­on of motor sym­ptoms, and the degree of upper and lower motor neu­ron dys­func­tion

Pro­vi­si­on, cough effi­ca­cy and tre­at­ment satis­fac­tion of mecha­ni­cal insuf­fla­ti­on-exsuf­fla­ti­on in a lar­ge mul­ti­cen­ter cohort of pati­ents with amyo­tro­phic late­ral scle­ro­sis

Self-assess­ment of amyo­tro­phic late­ral scle­ro­sis func­tion­al rating sca­le on the patient’s smart­phone pro­ves to be non-infe­ri­or to cli­nic data cap­tu­re

Shared pro­gno­stic infor­ma­ti­on in amyo­tro­phic late­ral scle­ro­sis — sys­te­ma­tic assess­ment of the pati­ents’ per­cep­ti­on of neu­ro­fi­la­ment light chain and the ALS func­tion­al rating sca­le

SOD1 gene scree­ning in ALS – fre­quen­cy of muta­ti­ons, pati­ents’ atti­tu­des to gene­tic infor­ma­ti­on and tran­si­ti­on to tofer­sen tre­at­ment in a mul­ti-cen­ter pro­gram

User expec­ta­ti­ons and expe­ri­en­ces of an assis­ti­ve robo­tic arm in amyo­tro­phic late­ral scle­ro­sis: a mul­ti­cen­ter obser­va­tio­nal stu­dy

Tofer­sen decrea­ses neu­ro­fi­la­ment levels sup­port­ing the patho­ge­ne­sis of the SOD1 p.D91A vari­ant in amyo­tro­phic late­ral scle­ro­sis pati­ents

Cli­ni­cal and pati­ent-repor­ted out­co­mes and neu­ro­fi­la­ment respon­se during tofer­sen tre­at­ment in SOD1-rela­ted ALS‑A mul­ti­cen­ter obser­va­tio­nal stu­dy over 18 months

Serum neu­ro­fi­la­ment light chain in distinct phe­no­ty­pes of amyo­tro­phic late­ral scle­ro­sis: A lon­gi­tu­di­nal, mul­ti­cen­ter stu­dy

Neu­ro­fi­la­ment light chain respon­se during the­ra­py with anti­sen­se oli­go­nu­cleo­ti­de Tofer­sen in SOD1-rela­ted ALS – tre­at­ment expe­ri­ence in cli­ni­cal prac­ti­ce

Per­for­mance of serum neu­ro­fi­la­ment light chain in a wide spec­trum of cli­ni­cal cour­ses of amyo­tro­phic late­ral scle­ro­sis – a cross-sec­tion­al mul­ti­cen­ter stu­dy

Remo­te digi­tal assess­ment of amyo­tro­phic late­ral scle­ro­sis func­tion­al rating sca­le – a mul­ti­cen­ter obser­va­tio­nal stu­dy

ALS­FRS-R-SE: an adapt­ed, anno­ta­ted, and self-expl­ana­to­ry ver­si­on of the revi­sed amyo­tro­phic late­ral scle­ro­sis func­tion­al rating sca­le

Use and sub­jec­ti­ve expe­ri­ence of the impact of motor-assis­ted move­ment exer­cisers in peo­p­le with amyo­tro­phic late­ral scle­ro­sis: a mul­ti­cen­ter obser­va­tio­nal stu­dy

Non-inva­si­ve and tra­cheo­sto­my inva­si­ve ven­ti­la­ti­on in amyo­tro­phic late­ral scle­ro­sis: Uti­liza­ti­on and sur­vi­val rates in a cohort stu­dy over 12 years in Ger­ma­ny

Sym­pto­ma­tic phar­ma­co­the­ra­py in ALS: data ana­ly­sis from a plat­form-based medi­ca­ti­on manage­ment pro­gram­me

Real world expe­ri­ence of pati­ents with amyo­tro­phic late­ral scle­ro­sis (ALS) in the tre­at­ment of spas­ti­ci­ty using tetrahydrocannabinol:cannabidiol (THC:CBD)

Publikationen mit Forschungsförderung durch die Boris Canessa ALS Stiftung

ALS motor phenotypes: a revised ‘OPM’ classification

Minimum important slowing of disease progression as determined by the ALS functional rating scale — a survey of patient expectations toward disease-modifying drugs in ALS

Motor phenotypes and neurofilament light chain in genetic amyotrophic lateral sclerosis—results from a multicenter screening program

Agreement Between the Harmonized and the Self-Explanatory Versions of the Revised ALS Functional Rating Scale in a Clinical Setting

Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis — assessment of treatment experience in a multicenter study

Motor phenotypes of amyotrophic lateral sclerosis — a three-determinant anatomical classification based on the region of onset, propagation of motor symptoms, and the degree of upper and lower motor neuron dysfunction

Provision, cough efficacy and treatment satisfaction of mechanical insufflation-exsufflation in a large multicenter cohort of patients with amyotrophic lateral sclerosis

Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient’s smartphone proves to be non-inferior to clinic data capture

Shared prognostic information in amyotrophic lateral sclerosis — systematic assessment of the patients’ perception of neurofilament light chain and the ALS functional rating scale

SOD1 gene screening in ALS – frequency of mutations, patients’ attitudes to genetic information and transition to tofersen treatment in a multi-center program

User expectations and experiences of an assistive robotic arm in amyotrophic lateral sclerosis: a multicenter observational study

Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients

Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS‑A multicenter observational study over 18 months

Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter study

Neurofilament light chain response during therapy with antisense oligonucleotide Tofersen in SOD1-related ALS – treatment experience in clinical practice

Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis – a cross-sectional multicenter study

Remote digital assessment of amyotrophic lateral sclerosis functional rating scale – a multicenter observational study

ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale

Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study

Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany

Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)